Literature DB >> 15133413

Minoxidil: an underused vasodilator for resistant or severe hypertension.

Domenic A Sica1.   

Abstract

Minoxidil is a direct vasodilator introduced in the early 1970s for the treatment of hypertension. It is capable of reducing blood pressure in most persons with resistant hypertension where therapy has failed with multidrug regimens. Minoxidil's effect can be limited because of an increase in pulse rate and/or sodium (and water) retention. The latter may prove quite debilitating in some patients. Thus, minoxidil is generally administered with both a diuretic and an agent that can keep pulse rate in check, such as a beta blocker or a combined alpha-beta blocker. The prominent tachycardia with minoxidil can aggravate myocardial ischemia and, if long-standing, leads to left ventricular hypertrophy. Minoxidil has a particularly annoying side effect of hypertrichosis that may limit its use, particularly among women. Minoxidil use is infrequently associated with the idiosyncratic onset of a pericardial effusion. If a patient's hypertension is severe enough to warrant minoxidil therapy, a hypertension specialist should probably become involved in the patient's care. The use of this medication should be limited in view of the availability of effective agents with fewer side effects. There is, however, a place for minoxidil in the treatment of resistant hypertension especially in patients with advanced renal disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133413      PMCID: PMC8109604          DOI: 10.1111/j.1524-6175.2004.03585.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  43 in total

1.  Hair loss with minoxidil withdrawal.

Authors:  B J Kidwai; M George
Journal:  Lancet       Date:  1992-09-05       Impact factor: 79.321

2.  Minoxidil for severe hypertension after failure of other hypotensive drugs.

Authors:  B L Devine; R Fife; P M Trust
Journal:  Br Med J       Date:  1977-09-10

3.  Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.

Authors:  M H Adams; W J Poynor; W R Garnett; H T Karnes; J J Ferry; K K Ryan; M A Sarkar
Journal:  Biopharm Drug Dispos       Date:  1998-11       Impact factor: 1.627

4.  Tissue distribution and hypotensive effects of minoxidil in normotensive rats.

Authors:  R G Pluss; J Orcutt; C A Chidsey
Journal:  J Lab Clin Med       Date:  1972-04

Review 5.  Minoxidil: a review of its pharmacological properties and therapeutic use.

Authors:  V M Campese
Journal:  Drugs       Date:  1981-10       Impact factor: 9.546

Review 6.  Minoxidil and the treatment of severe hypertension.

Authors:  W A Pettinger
Journal:  N Engl J Med       Date:  1980-10-16       Impact factor: 91.245

7.  The effects of the potassium channel opener minoxidil on renal electrolytes transport in the loop of henle.

Authors:  Tong Wang
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

8.  Very large pericardial effusion attributable to minoxidil: resolution without drainage of fluid.

Authors:  Arsalan Shirwany; Ivan A D'Cruz; Ahmad Munir
Journal:  Echocardiography       Date:  2002-08       Impact factor: 1.724

9.  Rapid control of severe hypertension with minoxidil.

Authors:  M A Alpert; J H Bauer
Journal:  Arch Intern Med       Date:  1982-11

10.  Hypertrichosis due to minoxidil.

Authors:  J L Burton; A Marshall
Journal:  Br J Dermatol       Date:  1979-11       Impact factor: 9.302

View more
  25 in total

1.  A hairy fall: syncope resulting from topical application of minoxidil.

Authors:  S W Dubrey; J VanGriethuysen; C M B Edwards
Journal:  BMJ Case Rep       Date:  2015-09-07

Review 2.  Pulmonary Hypertension and ATP-Sensitive Potassium Channels.

Authors:  Conor McClenaghan; Kel Vin Woo; Colin G Nichols
Journal:  Hypertension       Date:  2019-05-28       Impact factor: 10.190

Review 3.  K(ATP) channel therapeutics at the bedside.

Authors:  A Jahangir; Andre Terzic
Journal:  J Mol Cell Cardiol       Date:  2005-07       Impact factor: 5.000

4.  Evaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories.

Authors:  Kyuri Kim; Naseem Chini; David G Fairchild; Steven K Engle; William J Reagan; Sandra D Summers; Jon C Mirsalis
Journal:  Toxicol Pathol       Date:  2016-09-28       Impact factor: 1.902

Review 5.  Hypertension's 3 Dilemmas and 3 Solutions: Pharmacology of the Kidney in Hypertension.

Authors:  William A Pettinger
Journal:  J Cardiovasc Pharmacol       Date:  2017-03       Impact factor: 3.105

6.  Refractory shock following ingestion of topical minoxidil solution.

Authors:  T P Shashikala; Rajeshwar Singh; J Muthukrishnan
Journal:  Med J Armed Forces India       Date:  2016-03-29

7.  Hypertension in Cardiovascular and Kidney Disease.

Authors:  Joshua Botdorf; Kunal Chaudhary; Adam Whaley-Connell
Journal:  Cardiorenal Med       Date:  2011-07-30       Impact factor: 2.041

8.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 9.  Treatment resistant hypertension--investigation and conservative management.

Authors:  Franz Weber; Manfred Anlauf
Journal:  Dtsch Arztebl Int       Date:  2014-06-20       Impact factor: 5.594

Review 10.  Systemic hypertension and proteinuria in childhood chronic renal parenchymal disease: role of antihypertensive drug management.

Authors:  Giacomo D Simonetti; Laura Santoro; Alessandra Ferrarini; Laura Crosazzo-Franscini; Emilio Fossali; Mario G Bianchetti
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.